Imaging and Evaluation of Patients with High-risk Prostate Cancer

Overview

Journal Nat Rev Urol

Specialty Urology

Date 2015 Oct 21

PMID 26481576

Citations 16

Authors

Marc A Bjurlin

Andrew B Rosenkrantz

Luis S Beltran

Roy A Raad

Samir S Taneja

Affiliations

Soon will be listed here.

Abstract

Approximately 15% of men with newly diagnosed prostate cancer have high-risk disease. Imaging is critically important for the diagnosis and staging of these patients, and also for the selection of management. While established prostate cancer staging guidelines have increased the appropriate use of imaging, underuse for high-risk prostate cancer remains substantial. Several factors affect the utility of initial diagnostic imaging, including the variable definition of high-risk prostate cancer, variable guideline recommendations, poor accuracy of existing imaging tests, and the difficulty in validating imaging findings. Conventional imaging modalities, including CT and radionuclide bone scan, have been employed for local and metastatic staging, but their performance characteristics have generally been poor. Emerging modalities including multiparametricMRI, positron emission tomography (PET)-CT, and PET-MRI have shown increased diagnostic accuracy and could improve accuracy in staging patients with high-risk prostate cancer.

Citing Articles

Recommendations from Imaging, Oncology, and Radiology Organizations to Guide Management in Prostate Cancer: Summary of Current Recommendations.

Mew A, Chau E, Bera K, Ramaiya N, Tirumani S Radiol Imaging Cancer. 2025; 7(1):e240091.

PMID: 39792015 PMC: 11791666. DOI: 10.1148/rycan.240091.

Emerging Role of Nuclear Medicine in Prostate Cancer: Current State and Future Perspectives.

Volpe F, Nappi C, Piscopo L, Zampella E, Mainolfi C, Ponsiglione A Cancers (Basel). 2023; 15(19).

PMID: 37835440 PMC: 10571937. DOI: 10.3390/cancers15194746.

Has the Landscape of Immunotherapy for Prostate Cancer Changed? A Systematic Review and Post Hoc Analysis.

Ashraf M, Farwa U, Siddiqa M, Sarfraz A, Azeem N, Sarfraz Z Am J Mens Health. 2023; 17(2):15579883231165140.

PMID: 37002863 PMC: 10069001. DOI: 10.1177/15579883231165140.

F-PSMA-1007 PET/CT-derived semi-quantitative parameters for risk stratification of newly diagnosed prostate cancer.

Dong S, Li Y, Chen J, Li Y, Yang P, Li J Front Oncol. 2022; 12:1025930.

PMID: 36568229 PMC: 9768475. DOI: 10.3389/fonc.2022.1025930.

Current Opinion on the Use of Magnetic Resonance Imaging in Staging Prostate Cancer: A Narrative Review.

Michael J, Neuzil K, Altun E, Bjurlin M Cancer Manag Res. 2022; 14:937-951.

PMID: 35256864 PMC: 8898014. DOI: 10.2147/CMAR.S283299.

References

Makarov D, Desai R, Yu J, Sharma R, Abraham N, Albertsen P . The population level prevalence and correlates of appropriate and inappropriate imaging to stage incident prostate cancer in the medicare population. J Urol. 2011; 187(1):97-102. DOI: 10.1016/j.juro.2011.09.042. View

Crawford E, Stone N, Yu E, Koo P, Freedland S, Slovin S . Challenges and recommendations for early identification of metastatic disease in prostate cancer. Urology. 2014; 83(3):664-9. DOI: 10.1016/j.urology.2013.10.026. View

Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W . Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging. 2008; 35(10):1766-74. DOI: 10.1007/s00259-008-0788-z. View

Huang B, Law M, Khong P . Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology. 2009; 251(1):166-74. DOI: 10.1148/radiol.2511081300. View

Mullenders L, Atkinson M, Paretzke H, Sabatier L, Bouffler S . Assessing cancer risks of low-dose radiation. Nat Rev Cancer. 2009; 9(8):596-604. DOI: 10.1038/nrc2677. View

Davis G . Sensitivity of frozen section examination of pelvic lymph nodes for metastatic prostate carcinoma. Cancer. 1995; 76(4):661-8. DOI: 10.1002/1097-0142(19950815)76:4<661::aid-cncr2820760419>3.0.co;2-s. View

Schiepers C, Nuyts J, Bormans G, Dequeker J, Bouillon R, Mortelmans L . Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET. J Nucl Med. 1998; 38(12):1970-6. View

Rosenkrantz A, Chandarana H, Gilet A, Deng F, Babb J, Melamed J . Prostate cancer: utility of diffusion-weighted imaging as a marker of side-specific risk of extracapsular extension. J Magn Reson Imaging. 2012; 38(2):312-9. DOI: 10.1002/jmri.23972. View

Jager G, Ruijter E, de la Rosette J, Van De Kaa C . Amyloidosis of the seminal vesicles simulating tumor invasion of prostatic carcinoma on endorectal MR images. Eur Radiol. 1997; 7(4):552-4. DOI: 10.1007/s003300050202. View

10.

Chen Y, Pullambhatla M, Foss C, Byun Y, Nimmagadda S, Senthamizhchelvan S . 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011; 17(24):7645-53. PMC: 3243762. DOI: 10.1158/1078-0432.CCR-11-1357. View

11.

Mullerad M, Hricak H, Wang L, Chen H, Kattan M, Scardino P . Prostate cancer: detection of extracapsular extension by genitourinary and general body radiologists at MR imaging. Radiology. 2004; 232(1):140-6. DOI: 10.1148/radiol.2321031254. View

12.

Roach M, Lu J, Pilepich M, Asbell S, Mohiuddin M, Terry R . Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys. 2000; 47(3):609-15. DOI: 10.1016/s0360-3016(00)00578-2. View

13.

Briganti A, Passoni N, Ferrari M, Capitanio U, Suardi N, Gallina A . When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol. 2009; 57(4):551-8. DOI: 10.1016/j.eururo.2009.12.023. View

14.

Schuster D, Votaw J, Nieh P, Yu W, Nye J, Master V . Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007; 48(1):56-63. View

15.

Heck M, Souvatzoglou M, Retz M, Nawroth R, Kubler H, Maurer T . Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2013; 41(4):694-701. DOI: 10.1007/s00259-013-2634-1. View

16.

Cachovan M, Vija A, Hornegger J, Kuwert T . Quantification of 99mTc-DPD concentration in the lumbar spine with SPECT/CT. EJNMMI Res. 2013; 3(1):45. PMC: 3680030. DOI: 10.1186/2191-219X-3-45. View

17.

. Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA). Oncology (Williston Park). 2000; 14(2):267-72, 277-8, 280 passim. View

18.

Shreve P, Gross M . Imaging of the pancreas and related diseases with PET carbon-11-acetate. J Nucl Med. 1997; 38(8):1305-10. View

19.

Thoeny H, Froehlich J, Triantafyllou M, Huesler J, Bains L, Vermathen P . Metastases in normal-sized pelvic lymph nodes: detection with diffusion-weighted MR imaging. Radiology. 2014; 273(1):125-35. DOI: 10.1148/radiol.14132921. View

20.

Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F . 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology. 2010; 254(3):925-33. DOI: 10.1148/radiol.09090413. View